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Transient deactivation of ERK signalling is sufficient for stable
entry into G0 in primary avian fibroblasts
E.J. Black*, W. Clark* and D.A.F. Gillespie*†
Re-entry into the cell cycle from quiescence requires
the activation of mitogen-activated protein (MAP)
kinases of the extracellular-signal-regulated kinase
(ERK) family [1,2]. The relationship between ERK and
cell-cycle control is, however, complex, as ERK
activation can also lead to terminal differentiation [3] or
a senescence-like growth arrest [4]. Here, we report
that reversible cell-cycle exit induced by serum
withdrawal in primary avian fibroblasts is associated
with rapid deactivation of ERK, but ERK activity is
subsequently regenerated and sustained at high levels
in fully quiescent (G0) cells. As in proliferating cells,
ERK activation during G0 required the MAP kinase
kinase MEK and was partially dependent on cell
adhesion. Active, phosphorylated ERK was
concentrated in the nucleus in cycling cells, but was
largely confined to the cytoplasm during G0. This was
unexpected, as activatory phosphorylation mediated by
MEK is thought to play an important role in promoting
nuclear translocation [5,6]. These results indicate that
transient deactivation of ERK signalling can be
sufficient for stable cell-cycle exit, and that
MEK-mediated phosphorylation is not sufficient for
nuclear translocation of active ERK in G0. Cytoplasmic
sequestration may prevent active ERK from accessing
critical nuclear cell-cycle targets, thus allowing
quiescent or post-mitotic cells to retain ERK activity for
other physiological functions.
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Results and discussion
We examined the effect of growth-factor withdrawal on
ERK activity and cell-cycle progression in chick embryo
fibroblasts (CEFs), which express predominantly
ERK2 [7]. Transfer of CEF in exponential growth phase
(E, Figure 1a) to low serum (LS) medium led to a rapid
loss of active ERK (P-ERK) within 15 minutes, and a
progressive reduction in S-phase cells, as determined by
bromo-deoxyuridine (BrdU) labelling and flow cytome-
try (Figure 1b). This was due to accumulation of cells in
G0, as judged by the cessation of retinoblastoma (Rb)
protein phosphorylation (Figure 1a) and loss of the pro-
liferation-specific markers cyclin A and Cdc2 (data not
shown, [8]). Growth arrest was rapid, with a significant
decrease in DNA synthesis and accumulation of hypo-
phosphorylated Rb within 12 hours and essentially all of
the cells entering G0 within 48 hours (Figure 1a,b).
Although ERK was rapidly inactivated after transfer to LS
medium, activity began to return unexpectedly between 6
and 12 hours and increased progressively until the level of
Figure 1
ERK regulation in CEFs during cell-cycle exit induced by growth-factor
withdrawal. (a) ERK activity and Rb phosphorylation in CEFs after
transfer from growth medium (GM) to low serum (LS) medium.
E, exponentially growing cells; pRb, phosphorylated Rb protein.
(b) Percentage of S-phase cells in the cultures shown in (a). (c) ERK
activity in NIH3T3 and Rat-1 cells in growth medium, or 1 and 48 h
after transfer to LS medium. Replicate cultures of CEFs in growth
medium (containing 10% newborn calf serum and 1% chicken serum)
were transferred to low serum medium (containing 0.2% newborn calf
serum only) as described previously [8]. Rat-1 and NIH3T3 cells were
cultured and treated in essentially the same way but with the omission
of chicken serum. At the indicated times, Rb phosphorylation and the
percentage of S-phase cells were determined as described previously
[8]. Active ERK (P-ERK) was detected using a polyclonal antiserum
specific for the dual-phosphorylated, active form (Promega, V8031).
Total ERK was visualised using a non-discriminating polyclonal rabbit
antiserum (Sigma, M5670).
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active ERK in the fully quiescent cells was at least as high
as in proliferating cells (Figure 1a, compare LS 48 hours
with E). That these cultures were reversibly arrested in
G0 was evident from the effect of serum stimulation,
which induced a rapid, transient activation of ERK and a
relatively synchronous cell-cycle re-entry during which
the majority (> 85%) of cells re-phosphorylated Rb and
synthesised DNA within 20 hours (see Supplementary
material). Similar results were obtained using both poly-
and monoclonal antisera specific for the dual-phosphory-
lated, active form of ERK, and also when ERK activity
was measured biochemically using an immunoprecipitation
kinase assay (data not shown). Furthermore, this pattern
of regulation was not unique to CEFs, as a similar inacti-
vation of ERK followed by recovery after prolonged
growth-factor deprivation was seen in NIH3T3 cells and
Rat-1 fibroblasts (Figure 1c).
The initial rapid deactivation of ERK after serum with-
drawal (Figure 1a) suggested that continuous activation
through the Ras–Raf–MEK pathway was necessary to
sustain the basal level of ERK activity in cycling cells, pre-
sumably by counteracting tonic deactivation by MAP kinase
phosphatases [9]. Consistent with this prediction, ERK
activity declined rapidly when cycling cells were treated
with the MEK inhibitors PD098059 and U0126 (Figure 2a,
GM). In growth-factor-deprived cultures, ERK was equally
sensitive to inhibition by PD098059 and U0126 (Figure 2a,
LS), indicating that MEK activity was also present and
required to sustain ERK activity in quiescent cells. In fact,
similar levels of MEK and Raf activity were detected in
growing and fully quiescent cells, although both declined
transiently after transfer to LS medium and then increased
at later times in parallel with ERK (Figure 2b). This pattern
of regulation was also evident at the level of Ras, as similar
basal levels of Ras–GTP were detected in growing and qui-
escent cells in pull-down assays using a glutathione-S-trans-
ferase (GST)–Raf fusion protein as an affinity matrix [10],
yet Ras–GTP also diminished transiently after growth-factor
withdrawal (Figure 2b).
Serum contains multiple soluble ERK-pathway agonists
including polypeptide growth factors and lysophosphatidic
acid (LPA). Cell adhesion, however, also exerts profound
and complex effects on ERK-pathway regulation [11]. Inte-
grin engagement can stimulate ERK directly through both
Ras-dependent and Ras-independent mechanisms [11]. Cell
adhesion also potentiates activation of ERK by serum and
other soluble agonists by enhancing the efficiency of signal
propagation downstream of Ras at the level of Raf or MEK
[11,12]. It seemed possible therefore that the regeneration of
basal ERK activity after prolonged mitogen deprivation
might reflect a switch from predominantly serum-dependent
to adhesion-dependent Ras–Raf–MEK activation.
To evaluate this possibility, we investigated the adhesion
dependence of ERK activity in growing and quiescent
cells by suspension in semi-solid medium. As shown in
Figure 2c, suspension culture diminished the basal level
of active ERK both in the presence and absence of serum,
but there was no evidence that the decline was dispropor-
tionately greater in quiescent cells (Figure 2c, compare LS
with GM). Growth in suspension also blunted the ability
of serum to stimulate ERK activity, which, consistent with
previous studies [12], was associated with impaired activa-
tion of MEK (data not shown). Thus, these data argue
against adhesion as the principal source of the signal sus-
taining ERK activity after prolonged mitogen deprivation.
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Figure 2
Basal ERK activity requires continuous Ras–Raf–MEK signalling and is
partially dependent on substrate adhesion in both cycling and
quiescent CEFs. (a) Inhibition of ERK activity by the MEK inhibitors
PD098059 and U0126 in growing (GM) and quiescent (LS) cells.
(b) Effect of growth-factor withdrawal on MEK (top panel) and Raf
(middle panel) activity, and Ras–GTP levels (bottom panel). (c) Growth
in suspension inhibits ERK activity equally in cycling and quiescent
CEFs. Active ERK was visualised as described in the legend to
Figure 1. PD098059 and U0126 were used at 50 µM final
concentration. Active MEK was detected using an antiserum that
specifically recognises the dual-phosphorylated, active form
(New England Biolabs, 9121). Quantitation was by laser densitometry
of the autoradiograms, using a non-discriminating antibody
(New England Biolabs, 9122) to control for loading. Equal amounts of
cell extract were precipitated using c-Raf-specific antisera, and Raf
kinase activity in the precipitates was measured using a coupled assay,
essentially as described [15]. GTP-bound Ras was captured using
GST–Raf as an affinity matrix and quantitated by western blotting as
described previously [10]. Kinase activity and Ras–GTP levels were
quantitated by laser densitometry of the autoradiograms. Cells were
cultured in GM and LS medium either attached, or suspended in 0.5%
methocel. Where indicated, newborn calf serum (S) was added to
10% for 10 min before harvest.
Attached Suspension
10% S
LS 48 hGM GMLS 48 h
+ +– –– –
P-ERK2
P-ERK2
   Current Biology
GM
R
af
-1
 k
in
as
e 
ac
tiv
ity
(a
rb
itr
ar
y 
un
its
)
+S 10 min
+S 10 min
Active MEK
P
-M
E
K
1/
2
To
ta
l M
E
K
1/
2
R
as
–G
TP
(a
rb
itr
ar
y 
un
its
)
GM LS 48h
++– –
– –
P-ERK2
P-ERK2
+ +
0
0
0.5
1.0
2.0
4.0
3.0
0
0.5
1.0
1.5
2.0
2.5
3.0
1.0
1.5
GM 1 6 24 48 48
Time in LS (h)
1 6 24 48 48
GM
+S 10 min
1 6 24 48 48
(b)
(c)
(a)
PD098059
U0126
Raf-1 kinase
activity
Ras–GTP
Taken together, these results establish that the basal level
of active ERK in both growing and quiescent cells
depends on continuous Ras-Raf–MEK signalling, and that
a temporary interruption or diminution of this signalling is
likely to be the main determinant of the biphasic pattern
of ERK regulation during cell-cycle exit. Nevertheless, we
cannot rule out a contribution from other mechanisms
such as fluctuations in ERK or MEK phosphatase activity.
Inhibition of basal ERK activity leads to growth arrest in
cycling cells [1,13]. Therefore, it seems probable that the
initial deactivation of ERK is required to initiate cell-cycle
withdrawal. Conversely, as modest ERK activation can be
sufficient to induce DNA synthesis in growth-arrested
cells [4,14], these results imply that the ERK activity that
is regenerated in quiescent CEFs must be unable to
promote cell-cycle progression. 
To understand why this might be, we compared the sub-
cellular localisation of active ERK in growing and quies-
cent cells by confocal immunocytochemistry using a
monoclonal antibody specific for the dual-phosphorylated,
active form of ERK. This analysis (Figure 3) revealed that
active ERK was predominantly nuclear in growing cells,
but that nuclear staining diminished rapidly after transfer
to LS medium and was very weak or absent after 1 hour
when ERK activity was undetectable by western blotting
(Figure 1a). The overall level of staining increased after 24
and 48 hours. Active ERK in quiescent cells was largely
confined to the cytoplasm, where it appeared as fine
speckles or granules that, in some cases, were clearly
excluded from the nucleus (Figure 3). We are confident
that this cytoplasmic staining represents active ERK
because, as in growing cells, essentially all staining was
eliminated by a short treatment with U0126. Strikingly,
this situation was rapidly reversed by serum stimulation,
which led to a rapid increase in overall staining and 
reappearance of active ERK in the cell nucleus within
10 minutes, which correlated with the robust activation
detected in biochemical assays (see Supplementary
material). Thus, whereas active ERK is concentrated in
the nucleus in cycling cells, in quiescent cells it is 
predominantly confined to the cytoplasm. 
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Figure 3
Subcellular localisation of active ERK in cycling and quiescent CEFs.
Cycling CEFs (GM), transferred to LS medium for 1, 6, 24 or 48 h, or
quiescent cells maintained in LS medium for 48 h and then exposed to
10% newborn calf serum (+ S) for 10 min, were fixed and the
subcellular localisation of active, dual-phosphorylated ERK determined
by immunocytochemistry. CEFs were cultured on cover slips under the
indicated conditions, fixed in 3.7% formaldehyde in TBS
(20 mM Tris-HCl pH 7.6, 140 mM NaCl) and permeabilised using
0.5% triton-X100 in TBS. Active ERK was visualised using a
monoclonal antibody specific for ERK phosphorylated on both
threonine and tyrosine within the TEY motif (Sigma M8159, 1:100), in
combination with biotinylated anti-mouse immunoglobulin G (Vector
Laboratories, 1:750) and fluorescein-conjugated streptavidin (Vector
Laboratories, 1:100). Stained coverslips were mounted and viewed by
confocal microscopy. Nuclei are indicated by white arrows. Where
indicated, cells were treated with U0126 for 30 min before fixation.
These findings are unexpected in view of current under-
standing of the mechanism(s) controlling the subcellular
localisation of active ERK. Many studies have reported that
activation of the ERK pathway by diverse agonists results in
nuclear translocation of the active kinase [6]. Although the
mechanisms have not been fully elucidated, there is evi-
dence that ERK can enter the nucleus through both passive
diffusion and active transport [5]. Common to these mecha-
nisms, however, is the need to first release ERK from cyto-
plasmic sequestration, which is thought to result from
physical association with MEK [5]. It has recently been pro-
posed that MEK-mediated phosphorylation of ERK on
Tyr185 within the TEY regulatory phosphorylation sites is
sufficient to disrupt the interaction between MEK and
ERK, and thus release ERK from cytoplasmic sequestration
[5]. Our results, however, indicate that active ERK that has
already been phosphorylated at both of the TEY activatory
sites can nevertheless be retained in the cytoplasm. This
suggests either the existence of cytoplasmic anchors dis-
tinct from MEK that are capable of sequestering active
ERK, or that activatory phosphorylation is not sufficient to
release ERK from sequestration by MEK in quiescent cells.
Further work will be required to distinguish between these
alternatives. The differential localisation of ERK neverthe-
less provides an attractive explanation for the persistence
of active ERK in quiescent cells, as recent work has estab-
lished that ERK must localise to the nucleus in order to
execute its mitogenic function [2]. Thus, cytoplasmic
sequestration would be predicted to prevent active ERK
accessing critical nuclear cell-cycle regulatory substrates in
quiescent cells, effectively neutralising its mitogenic
potential. This represents an additional, previously
unrecognised, level at which the cell-cycle function of
ERK may be modulated during normal growth regulation.
Finally, our observations raise the question of what func-
tion ERK might fulfil in quiescent cells. Cell-cycle transi-
tions leading to proliferation and differentiation represent
the best-characterised biological functions of the ERK
pathway. It is clear, however, that ERK is involved in con-
trolling many other aspects of cell physiology. In particu-
lar, there is growing evidence that ERK has important
roles in regulating metabolism, cell motility, and in the
suppression of apoptosis. Cytoplasmic sequestration may
provide a mechanism through which active ERK can be
retained and re-deployed for such physiological functions
in quiescent or post-mitotic cells.
Supplementary material
Supplementary material including a figure showing ERK regulation
during serum-induced cell cycle re-entry from G0 in CEF is available at
http://current-biology.com/supmat/supmatin.htm. 
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